There's no question that for patients coping with a rare or complex disease or a compromised immune system, COVID-19 resulted in multiple new...
Entering our third year of coping with a pandemic that continues to disrupt lives brings into ever sharper focus the multiple difficulties involved for...
While it may seem as if 30 million Americans living with more than 7,000 distinct and rare medical conditions have little in common, there is much that...
Enzyme replacement therapy (ERT) is a treatment where replacement enzymes are utilized for patients who suffer from rare and complex conditions...
In the past 18 months, perhaps no advice to prevent the spread of COVID-19 has been more widely promoted and easier to implement than the act of...
As physicians have expressed with increasingly louder volume in the last decade, one of their primary sources of frustration continues to be the prior...
November is National Family Caregivers Month. This month serves to appreciate the role of family caregivers, address the issues they face, and further...
Maintaining, Monitoring, and Measuring a Smooth Patient Journey The journey of a rare disease patient is not an easy one from the start, frequently...
Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Sanofi has...
For more than 50 years, newborn screening for rare and congenital conditions has been part of healthcare in the United States. What began as a single...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)